Literature DB >> 20714907

Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN-γ secretion activity.

Yasuteru Kondo1, Yoshiyuki Ueno, Eiji Kakazu, Koju Kobayashi, Masaaki Shiina, Keiichi Tamai, Keigo Machida, Jun Inoue, Yuta Wakui, Koji Fukushima, Noriyuki Obara, Osamu Kimura, Tooru Shimosegawa.   

Abstract

BACKGROUND: Lymphotropic hepatitis C virus (HCV) infection of B and T cells might play an important role in the pathogenesis of hepatitis C. Recently, we showed that a lymphotropic HCV (SB strain) could infect established T-cell lines and B-cell lines. However, whether HCV replication interferes with cell proliferation and function in primary T lymphocytes is still unclear. AIM: The aim of this study was to analyze whether HCV replication in primary T lymphocytes affected their development, proliferation, and Th1 commitment.
METHODS: SB strain cell culture supernatant (2 × 10(4) copies/ml HCV) was used to infect several kinds of primary lymphocyte subsets. Mock, UV-irradiated SB-HCV, JFH-1 strain, and JFH-1 NS5B mutant, which could not replicate in T cells, were included as negative controls. Carboxyfluorescein succinimidyl ester (CFSE) and CD45RA double staining was used to evaluate the proliferative activity of CD4(+)CD45RA(+)CD45RO(-) naïve CD4(+) cells. Interferon (IFN)-γ and interleukin (IL)-10 secretion assays magnetic cell sorting (MACS) were carried out.
RESULTS: Negative strand HCV RNA was detected in CD4(+), CD14(+), and CD19(+) cells. Among CD4(+) cells, CD4(+)CD45RA(+)RO(-) cells (naïve CD4(+) cells) were most susceptible to replication of the SB strain. The levels of CFSE and CD45RA expression gradually declined during cell division in uninfected cells, while HCV-infected naïve CD4(+) cells expressed higher levels of CFSE and CD45RA than Mock or UV-SB infected naïve CD4(+) cells. Moreover, the production of IFN-γ was significantly suppressed in SB-infected naïve CD4(+) cells.
CONCLUSIONS: Lymphotropic HCV replication suppressed proliferation and development, including that towards Th1 commitment, in human primary naïve CD4(+) cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714907      PMCID: PMC4197795          DOI: 10.1007/s00535-010-0297-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly.

Authors:  T H Holmström; I Schmitz; T S Söderström; M Poukkula; V L Johnson; S C Chow; P H Krammer; J E Eriksson
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

2.  Hepatitis C virus infection in patients with non-Hodgkin's lymphoma.

Authors:  C Ferri; F Caracciolo; A L Zignego; L La Civita; M Monti; G Longombardo; F Lombardini; F Greco; E Capochiani; A Mazzoni
Journal:  Br J Haematol       Date:  1994-10       Impact factor: 6.998

3.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes.

Authors:  Keigo Machida; Kevin T-H Cheng; Vicky M-H Sung; Ki Jeong Lee; Alexandra M Levine; Michael M C Lai
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  CD81 is an entry coreceptor for hepatitis C virus.

Authors:  Emmanuel G Cormier; Fay Tsamis; Francis Kajumo; Robert J Durso; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

6.  Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells.

Authors:  Julien Laporte; Christine Bain; Patrick Maurel; Genevieve Inchauspe; Henri Agut; Annie Cahour
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

7.  Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection.

Authors:  Vicky M-H Sung; Shigetaka Shimodaira; Alison L Doughty; Gaston R Picchio; Huong Can; T S Benedict Yen; Karen L Lindsay; Alexandra M Levine; Michael M C Lai
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction.

Authors:  Yuan Hu; Azra Shahidi; Soon Park; Dennis Guilfoyle; Irvin Hirshfield
Journal:  Am J Clin Pathol       Date:  2003-01       Impact factor: 2.493

Review 9.  Immunopathology of hepatitis C.

Authors:  K M Chang; B Rehermann; F V Chisari
Journal:  Springer Semin Immunopathol       Date:  1997

10.  Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells.

Authors:  Yuka Miyasaka; Nobuyuki Enomoto; Masayuki Kurosaki; Naoya Sakamoto; Nobuhiko Kanazawa; Takahiro Kohashi; Eri Ueda; Shinya Maekawa; Hideki Watanabe; Namiki Izumi; Chifumi Sato; Mamoru Watanabe
Journal:  J Infect Dis       Date:  2003-11-11       Impact factor: 5.226

View more
  19 in total

1.  Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.

Authors:  Angela M Lam; Christine Espiritu; Eisuke Murakami; Veronique Zennou; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Nigel Bourne; Ronald L Veselenak; P Ganapati Reddy; Wonsuk Chang; Jinfa Du; Dhanapalan Nagarathnam; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

3.  Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Masashi Ninomiya; Keiichi Tamai; Yasuhito Tanaka; Jun Inoue; Eiji Kakazu; Koju Kobayashi; Osamu Kimura; Masahito Miura; Takeshi Yamamoto; Tomoo Kobayashi; Takehiko Igarashi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-16       Impact factor: 7.527

Review 4.  Direct effects of hepatitis C virus on the lymphoid cells.

Authors:  Yasuteru Kondo; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

5.  HCV infection and B-cell lymphomagenesis.

Authors:  Masahiko Ito; Hideki Kusunoki; Keiko Mochida; Kazunari Yamaguchi; Toshiaki Mizuochi
Journal:  Adv Hematol       Date:  2011-07-20

Review 6.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

7.  Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Hepat Res Treat       Date:  2011-06-14

8.  Biological significance of HCV in various kinds of lymphoid cells.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Int J Microbiol       Date:  2012-02-22

9.  Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro.

Authors:  Georgia Skardasi; Annie Y Chen; Tomasz I Michalak
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

10.  1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.

Authors:  Yasuteru Kondo; Takanobu Kato; Osamu Kimura; Tomoaki Iwata; Masashi Ninomiya; Eiji Kakazu; Masahito Miura; Takehiro Akahane; Yutaka Miyazaki; Tomoo Kobayashi; Motoyasu Ishii; Norihiro Kisara; Kumiko Sasaki; Haruo Nakayama; Takehiko Igarashi; Noriyuki Obara; Yoshiyuki Ueno; Tatsuki Morosawa; Tooru Shimosegawa
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.